Page last updated: 2024-09-05

lapatinib and Nail Diseases

lapatinib has been researched along with Nail Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bianca, D; Caro, G; Fabbrocini, G; Panariello, L	1
Garden, BC; Lacouture, ME; Wu, S	1
Lacouture, ME; Mitchell, EP; Perez-Soler, R; Van Cutsem, E	1

Reviews

2 review(s) available for lapatinib and Nail Diseases

Article	Year
The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis. Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:3 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Incidence; Lapatinib; Nail Diseases; Nails; Panitumumab; Quinazolines; Risk Factors	2012
Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:11 Suppl 5 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Lapatinib; Nail Diseases; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Telangiectasis	2007

Article

Year

The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.

Journal of the American Academy of Dermatology, 2012, Volume: 67, Issue:3

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Humans; Incidence; Lapatinib; Nail Diseases; Nails; Panitumumab; Quinazolines; Risk Factors

2012

Clinical presentation and pathophysiology of EGFRI dermatologic toxicities.

Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:11 Suppl 5

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Hair Diseases; Humans; Lapatinib; Nail Diseases; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Telangiectasis

2007

Other Studies

1 other study(ies) available for lapatinib and Nail Diseases

Article	Year
Phenol 8% solution for the treatment of epidermal growth factor receptor inhibitor-induced periungual pyogenic granulomas. Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2015, Volume: 150, Issue:6 Topics: Administration, Topical; Antineoplastic Agents; Breast Neoplasms; Caustics; Cautery; ErbB Receptors; Female; Granuloma, Pyogenic; Humans; Lapatinib; Middle Aged; Nail Diseases; Neoplasm Proteins; Phenol; Protein Kinase Inhibitors; Quinazolines; Toes	2015

Article

Year

Phenol 8% solution for the treatment of epidermal growth factor receptor inhibitor-induced periungual pyogenic granulomas.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2015, Volume: 150, Issue:6

Topics: Administration, Topical; Antineoplastic Agents; Breast Neoplasms; Caustics; Cautery; ErbB Receptors; Female; Granuloma, Pyogenic; Humans; Lapatinib; Middle Aged; Nail Diseases; Neoplasm Proteins; Phenol; Protein Kinase Inhibitors; Quinazolines; Toes

2015